HSP

Pfizer Inc. said Thursday that the U.S. Federal Trade Commission has requested additional information about its proposed acquisition of Hospira Inc.

Pfizer said the second request was an anticipated part of the regulatory approval process. The company said it continues to expect the deal to close in the second half of the year.

Pfizer struck a deal to buy Hospira in February for about $16 billion in cash.

Hospira is among the leading companies selling injectable drugs and biosimilars.

The deal would give Pfizer, which has been trying to build up its own businesses in those areas, the opportunity to expand and take leading positions in fast-growing markets.

Write to Chelsey Dulaney at chelsey.dulaney@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires